BioXcel Therapeutics's EBIT per Share for the
three
months ended in Mar. 2024 was $-0.75.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-4.73.
During the past 3 years, the average EBIT per Share Growth Rate was -14.90% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -34.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for BioXcel Therapeutics's EBIT per Share or its related term are showing as below:
BTAI'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -148.2 Med: -43.6 Max: -14.9
Current: -14.9
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of BioXcel Therapeutics was -14.90% per year. The lowest was -148.20% per year. And the median was -43.60% per year.
BTAI's 3-Year EBIT Growth Rate is ranked worse than 70.73% of 1305
companies
in the Biotechnology industry
Industry Median: 3.6
vs BTAI: -14.90
BioXcel Therapeutics EBIT per Share Historical Data
The historical data trend for BioXcel Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.73
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioXcel Therapeutics (NAS:BTAI) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
BioXcel Therapeutics EBIT per Share Related Terms
Thank you for viewing the detailed overview of BioXcel Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
BioXcel Therapeutics (BioXcel Therapeutics) Business Description
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BTAI has been successfully added to your 